加载中
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
前收盘价
US$0.7849
−US$0.0091 · -1.15%
盘中时间采用ET。市场数据可能有所延迟。
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
日内区间
当前US$0.7849
52周区间
当前US$0.7849
盘中时间采用ET。市场数据可能有所延迟。
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
日内区间
当前US$0.7849
52周区间
当前US$0.7849
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 1000 USD | — | — | — | — |
| 毛利 | −1000 USD | — | — | — | — |
| 研究与开发 | 1102.9万 USD | 1424.8万 USD | 3991 USD | 1.8万 USD | 1.7万 USD |
| 销售、一般及管理费用 | 1090.2万 USD | 1386.4万 USD | 1.14万 USD | 9680 USD | 9597 USD |
| 营业费用 | 2193万 USD | 6511.2万 USD | 1.63万 USD | 2.76万 USD | 2.66万 USD |
| 利息收入 | — | 40万 USD | 600 USD | — | — |
| 折旧和摊销 | 1000 USD | 6.3万 USD | 11.9万 USD | 16.9万 USD | 12.1万 USD |
| 营业利润 | −2193.1万 USD | −6511.2万 USD | −1.63万 USD | −2.76万 USD | −2.66万 USD |
| 净利润 | −4987.1万 USD | −6288.3万 USD | −1.57万 USD | −2.73万 USD | −2.62万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
